<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694092</url>
  </required_header>
  <id_info>
    <org_study_id>LARISA2020</org_study_id>
    <nct_id>NCT04694092</nct_id>
  </id_info>
  <brief_title>Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation</brief_title>
  <acronym>LARISA</acronym>
  <official_title>Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include patients with acute heart failure with reduced left ventricular&#xD;
      ejection fraction (&lt;40%) triggered by atrial fibrillation (AF) with a heart rate of &gt;130/min.&#xD;
      Patients in cardiogenic shock, critical state, or patients requiring emergent electric&#xD;
      cardioversion during the first 2 hours will be excluded. The patients will be randomized&#xD;
      (1:1) to a strategy of initial intensive heart rate control using continuous infusion of&#xD;
      landiolol and boluses of digoxin vs. standard approach to the rate control without the use of&#xD;
      landiolol. All patients will receive recommended pharmacotherapy of acute heart failure&#xD;
      (diuretics, nitrates, inotropes in patients with signs of low cardiac output - preferentially&#xD;
      milrinone or levosimendan). The patients will undergo hemodynamic monitoring, laboratory&#xD;
      testing, evaluation of symptoms, and quantification of lung water content by ultrasound for&#xD;
      48 hours. The study will test a hypothesis whether patients treated with initial intensive&#xD;
      heart rate control with the preferential use of landiolol will achieve faster heart rate&#xD;
      control, compensation of heart failure, and relief of heart failure symptoms without causing&#xD;
      hypotension or deterioration of heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedure:&#xD;
&#xD;
        1. Eligible patients with signed consent will be enrolled.&#xD;
&#xD;
        2. Baseline transthoracic echocardiography, laboratory testing, evaluation of subjective&#xD;
           dyspnea, lung water by ultrasound, chest x-ray, hemodynamic monitoring (details below)&#xD;
&#xD;
        3. Randomisation 1:1 to standard therapy vs. intensive heart rate control&#xD;
&#xD;
        4. Two hours of therapy with continous hemodynamic monitoring (blood pressure by arterial&#xD;
           line, cardiac output and stroke volume non-invasively by bioreactance)&#xD;
&#xD;
             1. Standard therapy (oral or intravenous beta-blockers other than landiolol while&#xD;
                avoiding hypotension or deterioration of hemodynamics, according to the preference&#xD;
                of the physician) with a bolus of 250-500mg of digoxin&#xD;
&#xD;
             2. Intensive heart rate control with the goal to achieve heart rate &lt;115 during the&#xD;
                first the hours, preferentially with continuous infusion of landiolol and a bolus&#xD;
                of 250-500mg of digoxin. The dose will be titrated according to the actual heart&#xD;
                rate and hemodynamic parameters (blood pressure, cardiac index, stroke volume&#xD;
                index). If possible, in both groups, electric cardioversion will be preferentially&#xD;
                delayed during the first 2 hours. Both groups will receive standard therapy of&#xD;
                acute heart failure (diuretics, inotropes if needed-preferentially milrinone or&#xD;
                levosimendan, nitrates..)&#xD;
&#xD;
        5. At 2 hours: evaluation of patients subjective dyspnea (primary clinical endpoint), heart&#xD;
           rate (primary endpoint), hearth rhythm and hemodynamics&#xD;
&#xD;
        6. After 2 hours, both groups can be treated according to the preference of the physician.&#xD;
&#xD;
        7. Symptoms, heart rate control, hemodynamics and lung congestion will be reevaluated at 12&#xD;
           and 48 hours&#xD;
&#xD;
        8. The study protocol will end after 48 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1 to intensive rate control with landiolol vs. standard therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate control</measure>
    <time_frame>during the first 2 hours</time_frame>
    <description>Achievement of heart rate &lt;115/min for at least 15 mins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in patient-reported symptoms</measure>
    <time_frame>at 2 hours</time_frame>
    <description>Change of patient-reported dyspnea evaluated 1-10 visual analog scale (1=unbearable dyspnea, 10=no symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant change of heart rate</measure>
    <time_frame>During the first 2 hours</time_frame>
    <description>Decrease of heart rate &gt;20% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate and heart rhythm</measure>
    <time_frame>heart rate measured at hours 2, 12 and 48 of the study protocol</time_frame>
    <description>the mean heart rate obtained from three measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - hypotension</measure>
    <time_frame>first 2 hours</time_frame>
    <description>Occurence of hypotension requiring reduction of the dose of betablockers or vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac index</measure>
    <time_frame>evaluated between baseline and hour 2</time_frame>
    <description>Change in cardiac index (L/m2) evaluated noninvasively by bioreactance (Starling SV, Cheetah Medical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stroke volume index</measure>
    <time_frame>evaluated between baseline and hour 2</time_frame>
    <description>Change in stroke volume index (ml/m2) evaluated noninvasively by bioreactance (Starling SV, Cheetah Medical)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation Rapid</condition>
  <condition>Acute Heart Failure</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Intensive rate control with landiolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive heart rate control using landiolol with the goal to achieve HR&lt;115 during the first 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard heart rate control with therapy other than landiolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive heart rate control with landiolol</intervention_name>
    <description>Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin</description>
    <arm_group_label>Intensive rate control with landiolol</arm_group_label>
    <other_name>Rapibloc, Amomed Pharma, Austria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard approach to heart rate control</intervention_name>
    <description>Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin</description>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute heart failure with reduced left ventricular ejection (&lt;40%)&#xD;
&#xD;
          -  atrial fibrillation with heart rate &gt;130/min lasting presumably &gt;12 hours and&#xD;
             presumably contributing to the acute heart failure&#xD;
&#xD;
          -  pulmonary congestion detected by auscultation, lung ultrasound or CXR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ongoing type 1. myocardial infarction&#xD;
&#xD;
          -  cardiogenic shock&#xD;
&#xD;
          -  presumed need for mechanical heart support during the first 48hours of the study&#xD;
&#xD;
          -  presumed need for electric cardioversion during the first 2 hours of the study&#xD;
&#xD;
          -  medication for heart rate control (beta-blockers, calcium channel blockers, digoxin)&#xD;
             or antiarrhythmics introduced &lt;24 hours before the study. Chronic therapy with these&#xD;
             will not be a contraindication for the study&#xD;
&#xD;
          -  thyreotoxicosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marek Sramko, MD., PhD.</last_name>
    <phone>+420776246127</phone>
    <email>marek.sramko@ikem.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Sramko, MD, PhD</last_name>
      <phone>+420776246127</phone>
      <email>marek.sramko@ikem.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Marek Sramko</investigator_full_name>
    <investigator_title>Head of the Department of Acute Cardiology</investigator_title>
  </responsible_party>
  <keyword>rate control</keyword>
  <keyword>betablockers</keyword>
  <keyword>landiolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Landiolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

